| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1474-4422(04)00678-7 |
| P698 | PubMed publication ID | 14980529 |
| P2093 | author name string | Beverly L Davidson | |
| Henry L Paulson | |||
| P2860 | cites work | Allele-specific silencing of a pathogenic mutant acetylcholine receptor subunit by RNA interference | Q24317061 |
| Asymmetry in the assembly of the RNAi enzyme complex | Q27860763 | ||
| A system for stable expression of short interfering RNAs in mammalian cells | Q27860875 | ||
| Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells | Q27860926 | ||
| RNA interference | Q28131798 | ||
| Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2 | Q28181376 | ||
| Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue | Q28506834 | ||
| Inactivation of the mouse Huntington's disease gene homolog Hdh | Q28509662 | ||
| Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice | Q28594828 | ||
| Expression profiling reveals off-target gene regulation by RNAi | Q29615965 | ||
| Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors | Q34028579 | ||
| Toxic proteins in neurodegenerative disease | Q34133493 | ||
| siRNA-mediated gene silencing in vitro and in vivo. | Q34150604 | ||
| RNAi functions in cultured mammalian neurons | Q34154748 | ||
| Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis | Q34224830 | ||
| In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins | Q34344453 | ||
| Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference | Q34520619 | ||
| Genetics of primary dystonia | Q34795185 | ||
| Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. | Q35111738 | ||
| The specifics of small interfering RNA specificity | Q35142626 | ||
| Genomewide view of gene silencing by small interfering RNAs | Q35142839 | ||
| Allele-specific silencing of dominant disease genes | Q35163317 | ||
| Approaches for the sequence-specific knockdown of mRNA. | Q35597089 | ||
| Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles | Q37069801 | ||
| Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach | Q40870377 | ||
| Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain | Q42280576 | ||
| Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery | Q43685007 | ||
| BACE1 Suppression by RNA Interference in Primary Cortical Neurons | Q44643912 | ||
| Local gene knockdown in the brain using viral-mediated RNA interference. | Q44666833 | ||
| A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency | Q45857796 | ||
| Toward therapy for DYT1 dystonia: allele-specific silencing of mutant TorsinA | Q73470858 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | RNA interference | Q201993 |
| gene silencing | Q1431332 | ||
| P304 | page(s) | 145-149 | |
| P577 | publication date | 2004-03-01 | |
| P1433 | published in | Lancet Neurology | Q15755067 |
| P1476 | title | Molecular medicine for the brain: silencing of disease genes with RNA interference | |
| P478 | volume | 3 |
| Q24810368 | A complementation method for functional analysis of mammalian genes |
| Q41385002 | ASPsiRNA: A Resource of ASP-siRNAs Having Therapeutic Potential for Human Genetic Disorders and Algorithm for Prediction of Their Inhibitory Efficacy |
| Q37270658 | Alkane-modified short polyethyleneimine for siRNA delivery |
| Q48536047 | BACE1 RNA interference improves spatial memory and attenuates Aβ burden in a streptozotocin-induced tau hyperphosphorylated rat model |
| Q36127993 | Brain stem excitatory and inhibitory signaling pathways regulating bronchoconstrictive responses |
| Q42289973 | CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington's Disease |
| Q24560011 | Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle |
| Q53178845 | Collision-induced dissociation of oligonucleotide anions fully modified at the 2'-position of the ribose: 2'-F/-H and 2'-F/-H/-OMe mix-mers. |
| Q37922198 | Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review |
| Q38076344 | Delivery systems and local administration routes for therapeutic siRNA. |
| Q38063945 | Drug delivery systems: Advanced technologies potentially applicable in personalized treatments |
| Q49731474 | Dynamics of CRISPR/Cas9-mediated genomic editing of the AXL locus in hepatocellular carcinoma cells. |
| Q41920871 | Effects of AAV-mediated knockdown of nNOS and GPx-1 gene expression in rat hippocampus after traumatic brain injury. |
| Q36013050 | Efficient down-regulation of glia maturation factor expression in mouse brain and spinal cord |
| Q37200224 | Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington's disease affected neuronal cells for reduction of huntingtin |
| Q40880975 | Gene silencing by RNAi in mouse Sertoli cells |
| Q26738497 | Gene, Stem Cell, and Alternative Therapies for SCA 1 |
| Q31023442 | Human gene therapy and imaging in neurological diseases |
| Q36045342 | Implementation of a chronic unilateral intraparenchymal drug delivery system in a swine model |
| Q36226774 | In vivo application of RNA interference: from functional genomics to therapeutics |
| Q37131550 | Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice |
| Q37670986 | Lipid-based nanotherapeutics for siRNA delivery |
| Q37425606 | Lipid-based systemic delivery of siRNA. |
| Q37704644 | Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference |
| Q36969152 | Nonviral approaches for neuronal delivery of nucleic acids. |
| Q24626259 | Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease |
| Q28273600 | Protein aggregation and neurodegenerative disease |
| Q28250480 | RNA interference and potential therapeutic applications of short interfering RNAs |
| Q36358342 | RNA interference in neuroscience: progress and challenges |
| Q37566034 | RNA-interference-based gene therapy approaches to HIV type-1 treatment: tackling the hurdles from bench to bedside |
| Q44964949 | RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. |
| Q34621268 | RNAi therapeutics: principles, prospects and challenges |
| Q37871417 | RNAi: a potential new class of therapeutic for human genetic disease |
| Q35990277 | Rational targeting for prion therapeutics. |
| Q36368045 | Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. |
| Q40355127 | Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs. |
| Q39958316 | Reversion of multidrug resistance in human glioma by RNA interference |
| Q42544646 | Selective cleavage of AChR cRNAs harbouring mutations underlying the slow channel myasthenic syndrome by hammerhead ribozymes. |
| Q33907953 | Self-assembled lipid nanomedicines for siRNA tumor targeting. |
| Q33243420 | Short interfering RNA (siRNA) as a novel therapeutic |
| Q36390831 | Silencing neurodegenerative disease: bringing RNA interference to the clinic |
| Q46798860 | Silencing primary dystonia: lentiviral-mediated RNA interference therapy for DYT1 dystonia. |
| Q34411459 | Tailor-made RNAi knockdown against triplet repeat disease-causing alleles |
| Q40379114 | Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model |
| Q36870572 | Technology insight: therapeutic RNA interference--how far from the neurology clinic? |
| Q37604903 | The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy. |
| Q48578985 | Toxic effects of lipid-mediated gene transfer in ventral mesencephalic explant cultures |
| Q34348958 | Unlocking the potential of the human genome with RNA interference |
| Q43546899 | Viral delivery of recombinant short hairpin RNAs |
| Q36918118 | miRNAs: from neurogeneration to neurodegeneration |
Search more.